 | • レポートコード：MRC2305B072 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、249ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に1,834.78百万ドルであった世界のがん悪液質市場規模が、2022年には1,960.65百万ドルに達し、2027年までに年平均7.11％成長して2,771.32百万ドルになると予測しています。当調査資料では、がん悪液質の世界市場について調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、治療法別分析（併用療法、コルチコステロイド、プロゲストゲン）、機能別分析（食欲刺激剤、減量安定剤）、流通チャネル別分析（病院売店、オンライン薬局、小売薬局）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの項目をまとめました。なお、当書に掲載されている企業情報には、AAVogen Inc.、AbbVie Inc.、Actimed Therapeutics Ltd.、ANI Pharmaceuticals, Inc.、Aphios Corporation、Artelo Biosciences Inc.、AstraZeneca PLC、AVEO Pharmaceuticals Inc.、Boehringer Ingelheim International GmbH、Bristol-Myers Squibb Companyなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のがん悪液質市場規模：治療法別 - 併用療法の市場規模 - コルチコステロイドの市場規模 - プロゲストゲンの市場規模 ・世界のがん悪液質市場規模：機能別 - 食欲刺激剤の市場規模 - 減量安定剤の市場規模 ・世界のがん悪液質市場規模：流通チャネル別 - 病院売店チャネルの市場規模 - オンライン薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界のがん悪液質市場規模：地域別 - 南北アメリカのがん悪液質市場規模 アメリカのがん悪液質市場規模 カナダのがん悪液質市場規模 ブラジルのがん悪液質市場規模 ... - アジア太平洋のがん悪液質市場規模 日本のがん悪液質市場規模 中国のがん悪液質市場規模 インドのがん悪液質市場規模 韓国のがん悪液質市場規模 台湾のがん悪液質市場規模 ... - ヨーロッパ/中東/アフリカのがん悪液質市場規模 イギリスのがん悪液質市場規模 ドイツのがん悪液質市場規模 フランスのがん悪液質市場規模 ロシアのがん悪液質市場規模 ... - その他地域のがん悪液質市場規模 ・競争状況 ・企業情報 |
The Global Cancer Cachexia Market size was estimated at USD 1,834.78 million in 2021 and expected to reach USD 1,960.65 million in 2022, and is projected to grow at a CAGR 7.11% to reach USD 2,771.32 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Cancer Cachexia to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Therapy, the market was studied across Combination Therapies, Corticosteroids, and Progestogens.
Based on Functionality, the market was studied across Appetite Stimulators and Weight Loss Stabilizers.
Based on Distribution Channel, the market was studied across Hospital Stores, Online Pharmacy, and Retail Pharmacy Stores.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cancer Cachexia market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Cachexia Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Cachexia Market, including AAVogen Inc., AbbVie Inc., Actimed Therapeutics Ltd., ANI Pharmaceuticals, Inc., Aphios Corporation, Artelo Biosciences Inc., AstraZeneca PLC, AVEO Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Fresenius Kabi AG, Helsinn Healthcare SA, INOVIO Pharmaceuticals Inc., Marsala Biotech Inc., Merck & Co. Inc., MetaFines Co., Ltd., NGM Biopharmaceuticals Inc., Pfizer Inc., Tetra Bio-Pharma, and Teva Pharmaceutical Industries Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Cancer Cachexia Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Cachexia Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Cachexia Market?
4. What is the competitive strategic window for opportunities in the Global Cancer Cachexia Market?
5. What are the technology trends and regulatory frameworks in the Global Cancer Cachexia Market?
6. What is the market share of the leading vendors in the Global Cancer Cachexia Market?
7. What modes and strategic moves are considered suitable for entering the Global Cancer Cachexia Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cachexia amongst the geriatric population
5.1.1.2. Presence of adequate reimbursement policies
5.1.1.3. Improving healthcare infrastructure and rise in awareness to treat cancer cachexia
5.1.2. Restraints
5.1.2.1. High cost of treatment
5.1.3. Opportunities
5.1.3.1. Technological advancements for the treatment of cancer cachexia
5.1.3.2. Rising number of research and development activities for the discovery of therapeutic drugs
5.1.4. Challenges
5.1.4.1. Implementation of stringent regulatory requirements and lengthy FDA approval
5.2. Cumulative Impact of COVID-19
6. Cancer Cachexia Market, by Therapy
6.1. Introduction
6.2. Combination Therapies
6.3. Corticosteroids
6.4. Progestogens
7. Cancer Cachexia Market, by Functionality
7.1. Introduction
7.2. Appetite Stimulators
7.3. Weight Loss Stabilizers
8. Cancer Cachexia Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Stores
8.3. Online Pharmacy
8.4. Retail Pharmacy Stores
9. Americas Cancer Cachexia Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cancer Cachexia Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cancer Cachexia Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AAVogen Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AbbVie Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Actimed Therapeutics Ltd.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. ANI Pharmaceuticals, Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Aphios Corporation
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Artelo Biosciences Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. AstraZeneca PLC
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. AVEO Pharmaceuticals Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Boehringer Ingelheim International GmbH
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Bristol-Myers Squibb Company
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Eli Lilly and Company
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Fresenius Kabi AG
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Helsinn Healthcare SA
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. INOVIO Pharmaceuticals Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Marsala Biotech Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Merck & Co. Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. MetaFines Co., Ltd.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. NGM Biopharmaceuticals Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Pfizer Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Tetra Bio-Pharma
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Teva Pharmaceutical Industries Ltd.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing